Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
38.02
-0.91 (-2.34%)
At close: Oct 2, 2026, 4:00 PM EDT
37.58
-0.44 (-1.16%)
After-hours: Oct 2, 2026, 7:32 PM EDT
Xenon Pharmaceuticals Revenue
In the year 2025, Xenon Pharmaceuticals had annual revenue of $7.50M.
Revenue (ttm)
$7.50M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
370
Market Cap
3.68B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.50M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 9.43M | -9.00M | -48.83% |
| Dec 31, 2021 | 18.44M | -13.73M | -42.68% |
| Dec 31, 2020 | 32.17M | 25.34M | 371.02% |
| Dec 31, 2019 | 6.83M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 311.00K | -1.49M | -82.75% |
| Dec 31, 2016 | 1.80M | -13.77M | -88.43% |
| Dec 31, 2015 | 15.58M | -12.79M | -45.09% |
| Dec 31, 2014 | 28.37M | 1.01M | 3.71% |
| Dec 31, 2013 | 27.36M | 13.05M | 91.19% |
| Dec 31, 2012 | 14.31M | 7.39M | 106.82% |
| Dec 31, 2011 | 6.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Acadia Pharmaceuticals | 1.14B |
| Telix Pharmaceuticals | 890.79M |
| Tarsus Pharmaceuticals | 606.33M |
| IDEAYA Biosciences | 234.13M |
| Tango Therapeutics | 53.81M |
| Relay Therapeutics | 10.35M |
XENE News
- 1 day ago - Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - Xenon Pharmaceuticals CFO buys 15,000 shares - TheFly
- 3 days ago - Xenon Pharmaceuticals CEO buys 30,000 shares - TheFly
- 5 days ago - Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors - Newsfile Corp
- 11 days ago - Xenon Pharmaceuticals Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit - Transcripts
- 11 days ago - XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law - Business Wire
- 11 days ago - Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE) - PRNewsWire
- 12 days ago - Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors - GlobeNewsWire